AR054448A1 - Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis - Google Patents
Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasisInfo
- Publication number
- AR054448A1 AR054448A1 ARP060101851A ARP060101851A AR054448A1 AR 054448 A1 AR054448 A1 AR 054448A1 AR P060101851 A ARP060101851 A AR P060101851A AR P060101851 A ARP060101851 A AR P060101851A AR 054448 A1 AR054448 A1 AR 054448A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- arsenious acid
- treatment
- metastasis
- sodium salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Luminescent Compositions (AREA)
- Otolaryngology (AREA)
Abstract
Composiciones farmacéuticas y métodos para el tratamiento de enfermedades urogenitales y metástasis osea en un humano, dicha composicion farmacéutica contiene una cantidad efectiva de sal de metal alcalino o alcalino térreo de ácido arsenioso y/o un adyuvante farmacéuticamente aceptable. De acuerdo con la presente, la sal de metal alcalino de ácido arsenioso es meta-arsenito de sodio (AsSO2Na) o meta-arsenito de potasio (AsO2K). La cantidad efectiva de sal de metal alcalino o alcalino térreo de ácido arsenioso es 0,0001-1500 mg/kg, preferentemente 1-1100 mg/kg, más preferentemente 1-150 mg/kg, y aun más preferentemente 50-100 mg/kg de peso corporal/día. La forma de administracion de las composiciones farmacéuticas de la presente es preferentemente oral, tales como una tableta, cápsula, polvo y/o solucion con un portador, diluyente o excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05076071A EP1721615A1 (en) | 2005-05-09 | 2005-05-09 | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054448A1 true AR054448A1 (es) | 2007-06-27 |
Family
ID=35197739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101851A AR054448A1 (es) | 2005-05-09 | 2006-05-09 | Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20090011047A1 (es) |
| EP (5) | EP1721615A1 (es) |
| JP (1) | JP5026408B2 (es) |
| KR (3) | KR20160035101A (es) |
| CN (2) | CN101277707A (es) |
| AR (1) | AR054448A1 (es) |
| AU (1) | AU2006244767B2 (es) |
| BR (1) | BRPI0608716A2 (es) |
| CA (3) | CA2926846C (es) |
| CY (2) | CY1113475T1 (es) |
| DK (2) | DK3067068T3 (es) |
| ES (2) | ES2394264T3 (es) |
| HK (1) | HK1109736A1 (es) |
| HU (1) | HUE046029T2 (es) |
| IL (3) | IL187220A (es) |
| LT (1) | LT3067068T (es) |
| PL (2) | PL3067068T3 (es) |
| PT (1) | PT1885380E (es) |
| RU (1) | RU2401662C2 (es) |
| SG (5) | SG10201602555WA (es) |
| SI (2) | SI1885380T1 (es) |
| TW (5) | TWI574692B (es) |
| WO (1) | WO2006121280A1 (es) |
| ZA (1) | ZA200710559B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8945505B2 (en) | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| US20120045520A1 (en) * | 2008-08-21 | 2012-02-23 | Sang Bong Lee | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| RU2568834C2 (ru) * | 2009-09-10 | 2015-11-20 | Коминокс, Инк. | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами |
| KR20120048706A (ko) * | 2009-09-18 | 2012-05-15 | 코미녹스 인코포레이티드 | 뇌종양 치료 방법 |
| EP2524226A1 (en) | 2010-01-13 | 2012-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Promyelocytic leukemia protein as a redox sensor |
| WO2012095379A1 (en) * | 2011-01-11 | 2012-07-19 | Universität Basel | Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression |
| US20120251628A1 (en) * | 2011-03-30 | 2012-10-04 | Young Joo Min | Compositions and methods for treatment of cancer |
| KR101309844B1 (ko) * | 2013-03-15 | 2013-09-23 | 박상채 | 항암 활성 증진용 한약재 및 이의 제조방법 |
| RU2618405C1 (ru) * | 2015-12-31 | 2017-05-03 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств |
| US10806768B2 (en) * | 2016-05-26 | 2020-10-20 | Stephen N. Pitcher | Composition for promoting metallothionein production |
| NZ752214A (en) | 2016-12-01 | 2022-11-25 | Eupharma Pty Ltd | Arsenic compositions |
| AR114596A1 (es) * | 2018-03-22 | 2020-09-23 | Komipharm Int Australia Pty Ltd | Composición farmacéutica y método de fabricación |
| WO2019234112A1 (en) * | 2018-06-05 | 2019-12-12 | Katholieke Universiteit Leuven | Combination treatment of arsenic oxide and antiandrogens |
| CN115243692A (zh) * | 2020-02-16 | 2022-10-25 | 科微范国际澳大利亚私人有限公司 | 使用偏亚砷酸盐的治疗方法 |
| KR20220020635A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 외용제 조성물 |
| KR20220020637A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물 |
| KR20220020633A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 주사제 조성물 |
| CN112336746A (zh) * | 2020-10-23 | 2021-02-09 | 内蒙古科技大学包头医学院 | 一种膀胱癌灌注化疗药物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| FR2431686A1 (fr) | 1978-07-20 | 1980-02-15 | Nestle Sa Soc Ass Tech Prod | Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| KR930001917A (ko) * | 1991-07-26 | 1993-02-22 | 김두석 | 악성 종양 치료제의 제조방법 |
| EP0804928B1 (en) * | 1994-02-18 | 2004-10-20 | Tamara Vasilievna Vorobieva | Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system |
| DK1378240T3 (da) * | 1997-10-15 | 2008-12-08 | Polarx Biopharmaceuticals Inc | Farmaceutiske præparater omfattende arsentrioxid til behandling af multipelt myelom |
| ES2399480T3 (es) | 1997-11-10 | 2013-04-01 | Memorial Sloan-Kettering Cancer Center | Procedimiento de producción de formulaciones de trióxido de arsénico |
| CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
| TW200408407A (en) | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| MXPA04009898A (es) * | 2002-04-10 | 2005-06-20 | Korea Microbiological Lab Ltd | Composicion farmaceutica que comprende arsenita para el tratamiento de tumores malignos. |
| KR100632250B1 (ko) * | 2004-02-16 | 2006-10-11 | 정태호 | 비소 화합물을 유효성분으로 하는 항암제 |
| US20060104292A1 (en) | 2004-11-15 | 2006-05-18 | Gupta Vivek G | System and methods for supporting multiple communications interfaces with single client interface |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US8945505B2 (en) | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| RU2568834C2 (ru) | 2009-09-10 | 2015-11-20 | Коминокс, Инк. | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами |
-
2005
- 2005-05-09 EP EP05076071A patent/EP1721615A1/en not_active Withdrawn
-
2006
- 2006-05-09 HU HUE16162414A patent/HUE046029T2/hu unknown
- 2006-05-09 SI SI200631444T patent/SI1885380T1/sl unknown
- 2006-05-09 EP EP16162414.3A patent/EP3067068B1/en active Active
- 2006-05-09 JP JP2008511051A patent/JP5026408B2/ja active Active
- 2006-05-09 BR BRPI0608716-7A patent/BRPI0608716A2/pt not_active Application Discontinuation
- 2006-05-09 RU RU2007145489/14A patent/RU2401662C2/ru active
- 2006-05-09 SG SG10201602555WA patent/SG10201602555WA/en unknown
- 2006-05-09 SG SG2012003091A patent/SG177983A1/en unknown
- 2006-05-09 CA CA2926846A patent/CA2926846C/en active Active
- 2006-05-09 SG SG2011075330A patent/SG175633A1/en unknown
- 2006-05-09 PL PL16162414T patent/PL3067068T3/pl unknown
- 2006-05-09 SI SI200632358T patent/SI3067068T1/sl unknown
- 2006-05-09 DK DK16162414T patent/DK3067068T3/da active
- 2006-05-09 TW TW104124162A patent/TWI574692B/zh active
- 2006-05-09 CN CNA2006800250320A patent/CN101277707A/zh active Pending
- 2006-05-09 LT LT16162414T patent/LT3067068T/lt unknown
- 2006-05-09 PL PL06732912T patent/PL1885380T3/pl unknown
- 2006-05-09 WO PCT/KR2006/001731 patent/WO2006121280A1/en active Application Filing
- 2006-05-09 SG SG10201405278SA patent/SG10201405278SA/en unknown
- 2006-05-09 TW TW095116432A patent/TWI386214B/zh active
- 2006-05-09 TW TW103132530A patent/TWI522105B/zh active
- 2006-05-09 EP EP11165670.8A patent/EP2361628A1/en not_active Ceased
- 2006-05-09 PT PT06732912T patent/PT1885380E/pt unknown
- 2006-05-09 EP EP06732912A patent/EP1885380B1/en active Active
- 2006-05-09 AU AU2006244767A patent/AU2006244767B2/en active Active
- 2006-05-09 EP EP14166070.4A patent/EP2762145A1/en not_active Ceased
- 2006-05-09 ES ES06732912T patent/ES2394264T3/es active Active
- 2006-05-09 AR ARP060101851A patent/AR054448A1/es unknown
- 2006-05-09 CA CA2608035A patent/CA2608035C/en active Active
- 2006-05-09 CN CN201510064962.8A patent/CN104758312A/zh active Pending
- 2006-05-09 TW TW105102103A patent/TW201615200A/zh unknown
- 2006-05-09 TW TW101132058A patent/TWI539957B/zh active
- 2006-05-09 KR KR1020167007395A patent/KR20160035101A/ko not_active Application Discontinuation
- 2006-05-09 SG SG10202100785PA patent/SG10202100785PA/en unknown
- 2006-05-09 DK DK06732912.8T patent/DK1885380T3/da active
- 2006-05-09 KR KR1020077028751A patent/KR101413731B1/ko active IP Right Grant
- 2006-05-09 CA CA2840609A patent/CA2840609C/en active Active
- 2006-05-09 US US11/631,962 patent/US20090011047A1/en not_active Abandoned
- 2006-05-09 KR KR1020157017831A patent/KR20150085122A/ko not_active Application Discontinuation
- 2006-05-09 ES ES16162414T patent/ES2754372T3/es active Active
-
2007
- 2007-11-07 IL IL187220A patent/IL187220A/en active IP Right Grant
- 2007-12-04 ZA ZA200710559A patent/ZA200710559B/xx unknown
-
2008
- 2008-03-17 HK HK08103067.4A patent/HK1109736A1/xx unknown
-
2012
- 2012-10-10 CY CY20121100940T patent/CY1113475T1/el unknown
-
2013
- 2013-12-17 IL IL229975A patent/IL229975A/en active IP Right Grant
-
2016
- 2016-03-22 IL IL244728A patent/IL244728A0/en unknown
- 2016-03-22 US US15/077,373 patent/US11464859B2/en active Active
-
2019
- 2019-11-06 CY CY20191101162T patent/CY1122522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054448A1 (es) | Composiciones farmaceuticas que comprenden acido arsenioso, su sal de sodio y sus derivados destinada al tratamiento de cancer urogenital y de su metastasis | |
| BRPI0414311A (pt) | formas de dosagem de liberação controlada | |
| EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
| NI201200172A (es) | Activadores de guanilato ciclasa soluble | |
| MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
| MX346879B (es) | Formulaciones de ketorolaco listas para su uso. | |
| RU2016122609A (ru) | Составы соединений азаиндола | |
| GB0509317D0 (en) | Pharmaceutical formulation of apomorphine | |
| GEP20135734B (en) | Pharmaceutical composition containing salt of strontium, vitamin d and cyclodextrin | |
| PL2018379T3 (pl) | Sole skopiny oraz ich zastosowanie w sposobach wytwarzania N-demetylo-tiotropium i bromku tiotropium | |
| RS54244B1 (en) | NALBUFINE BASED FORMULATIONS AND THEIR USE | |
| JO3406B1 (ar) | عملية لتصنيع منتج صيدلاني يشتمل على حمض الستريك ،أكسيد ماغنسيوم، بيكربونات بوتاسيوم وبيكو كبريتات صوديوم، تركيبة صيدلانية تشتمل على حبيبات متحصل عليها بواسطة هذه العملية ومنتجات وسيطة منها | |
| UA102885C2 (ru) | Таблетка для орального введения, которая содержит тамсулозин и солифенацин | |
| IN2012DN02502A (es) | ||
| RU2013154355A (ru) | Способ лечения мезотелиомы ингибитором рi3к | |
| IN2015DN03921A (es) | ||
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| PE20081895A1 (es) | Regimen anticonceptivo oral | |
| MX2014001065A (es) | Formulaciones de (trimetoxifenilamino) pirimidilino nuevas. | |
| MXPA05013607A (es) | Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos. | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| RU2015111491A (ru) | Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира | |
| DK2091520T3 (da) | Oral doseringsform omfattende trisubstituerede glycerol-forbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |